Primary hyperparathyroidism: Difference between revisions

Jump to navigation Jump to search
Line 42: Line 42:


===Surgery===
===Surgery===
A consensus statement in 2002 recommended the following indications for surgery<ref name="pmid12466320">{{cite journal |author=Bilezikian JP, Potts JT, Fuleihan Gel-H, ''et al'' |title=Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century |journal=J. Clin. Endocrinol. Metab. |volume=87 |issue=12 |pages=5353-61 |year=2002 |pmid=12466320 |doi=}}</ref>:
* Serum calcium (above upper limit of normal): 1.0 mg/dl
* 24-h urinary calcium >400 mg
* Creatinine clearance reduced by 30% compared with age-matched subjects.
* Bone mineral density t-score <-2.5 at any site
* Age <50
More recently, three [[randomized controlled trial]]s have studied the role of surgery in patients with asymptomatic hyperparathyroidism. The largest study reported that surgery showed increase in bone mass, but no improvement in quality of life after one to two years among patients with<ref name="pmid17284629">{{cite journal |author=Bollerslev J, Jansson S, Mollerup CL, ''et al'' |title=Medical observation, compared with parathyroidectomy, for asymptomatic primary hyperparathyroidism: a prospective, randomized trial |journal=J. Clin. Endocrinol. Metab. |volume=92 |issue=5 |pages=1687-92 |year=2007 |pmid=17284629 |doi=10.1210/jc.2006-1836}}</ref>:
* Untreated, asymptomatic primary hyperparathyroidism
* Serum calcium between 2.60 - 2.85 mmol/liter (10.4 - 11.4 mg/dl)
* Age between 50 and 80 yr
* No medications interfering with Ca metabolism
* No hyperparathyroid bone disease
* No previous operation in the neck
* Creatinine level < 130 µmol/liter (<1.47 mg/dl)
Two other [[randomized controlled trial | trials]] reported improvements in bone density and some improvement in quality of life with surgery.<ref name="pmid17535997">{{cite journal |author=Ambrogini E, Cetani F, Cianferotti L, ''et al'' |title=Surgery or surveillance for mild asymptomatic primary hyperparathyroidism: a prospective, randomized clinical trial |journal=J. Clin. Endocrinol. Metab. |volume=92 |issue=8 |pages=3114-21 |year=2007 |pmid=17535997 |doi=10.1210/jc.2007-0219}}</ref><ref name="pmid15531491">{{cite journal |author=Rao DS, Phillips ER, Divine GW, Talpos GB |title=Randomized controlled clinical trial of surgery versus no surgery in patients with mild asymptomatic primary hyperparathyroidism |journal=J. Clin. Endocrinol. Metab. |volume=89 |issue=11 |pages=5415-22 |year=2004 |pmid=15531491 |doi=10.1210/jc.2004-0028}}</ref>


===Future therapies===
===Future therapies===

Revision as of 17:29, 20 September 2012

For patient information click here

Primary hyperparathyroidism
Thyroid and parathyroid.
ICD-10 E21.0
ICD-9 252.01
DiseasesDB 6283
MeSH D049950

Template:Primary hyperparathyroidism Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Primary hyperparathyroidism causes hypercalcemia (elevated blood calcium levels) through the excessive secretion of parathyroid hormone (PTH), usually by an adenoma (benign tumors) of the parathyroid glands. Its incidence is approximately 42 per 100,000 people. It is almost exactly three times as common in women as men.

Signs and Symptoms

The signs and symptoms of primary hyperparathyroidism are those of hypercalcemia. They are classically summarized by the mnemonic "stones, bones, abdominal groans and psychic moans".

Other signs include proximal muscle weakness, itching, and band keratopathy of the eyes.

Diagnosis

The diagnosis of primary hyperparathyroidism is made by blood tests. Serum calcium levels are elevated.

Complications

The classic bone disease in hyperparathyroidism is osteitis fibrosa cystica, which results in pain and sometimes pathological fractures. Other bone diseases associated with hyperparathyroidism are osteoporosis, osteomalacia, and arthritis.

Treatment

Treatment is usually surgical removal of the gland(s) containing adenomas.

Medications

Medications include estrogen replacement therapy in postmenopausal women and bisphosphonates. Bisphosphonates may improve bone turnover.[2]

Surgery

Future therapies

Future developments such as calcimemetic agents (e.g. cinacalcet) which activate the parathyroid calcium-sensing receptor may offer a good alternative to surgery.

Related Chapters

References

  1. Stefenelli T, Abela C, Frank H; et al. (1997). "Cardiac abnormalities in patients with primary hyperparathyroidism: implications for follow-up". J. Clin. Endocrinol. Metab. 82 (1): 106–12. PMID 8989242.
  2. Khan AA, Bilezikian JP, Kung AW; et al. (2004). "Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial". J. Clin. Endocrinol. Metab. 89 (7): 3319–25. doi:10.1210/jc.2003-030908. PMID 15240609.

sv:Primär hyperparatyreos


Template:WikiDoc Sources